5/27/2020 4:03:12 PM
Arena Pharmaceuticals Announces Proposed Public Offering Of Common Stock
5/26/2020 8:32:12 AM
Arena Completes Full Enrollment Of Etrasimod Phase 2 ADVISE Trial Evaluating Etrasimod For Atopic Dermatitis
5/7/2020 4:07:44 PM
Arena Pharma Q1 Loss/share $2.00 Vs. Profit $12.10 Year Ago
4/24/2020 9:03:10 AM
Arena Grants Inducement Stock Options To Certain New Employees
2/26/2020 4:03:23 PM
Arena Pharma Q4 Loss/share $1.76 Vs. Profit $1.35 Year Ago
1/16/2020 9:03:13 AM
FDA Grants Fast Track Designation To Arena' APD418 For Development In Decompensated Heart Failure Patients
1/13/2020 4:10:48 PM
Arena Pharmaceuticals Appoints Joan Schmidt As EVP, General Counsel And Secretary
1/2/2020 8:32:36 AM
Arena Pharma And Beacon Discovery Expand Partnership To Focus On Multiple Immune And Inflammatory Targets
11/7/2019 4:05:05 PM
Arena Pharma Q3 Loss/share $1.46 Vs. Loss $0.70 Year Ago
11/6/2019 8:35:01 AM
Arena Presents New Data Highlighting Human Mass Balance And Metabolism Profile Of Etrasimod
10/28/2019 8:31:59 AM
Arena Pharmaceuticals Says First Subject Dosed In Phase 2 ADVISE Trial Evaluating Etrasimod
10/18/2019 3:09:26 AM
Arena Pharma To Present New Open-label Extension Data From Phase 2 OASIS Trial For Etrasimod At UEG Week
9/26/2019 8:38:40 AM
Arena Pharmaceuticals Presents New Data From Phase 2 OASIS Trial For Etrasimod